Description: Mouse Monoclonal human CD235a Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Description: Mouse Monoclonal human CD8 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Description: Mouse Monoclonal Human VEGI Antibody Biotin Conjugated, Flow Validated. Validated in WB and tested in Human.

Description: Mouse Monoclonal human CD3 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Description: Mouse Monoclonal human CD20 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Description: Mouse Monoclonal human CD10 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Description: Mouse Monoclonal human CD57 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Description: Mouse Monoclonal human HLA-DR Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Description: Mouse Monoclonal human CD55/Daf Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Description: Mouse Monoclonal human CD33/Siglec 3 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Description: Mouse Monoclonal human CD22/Siglec 2 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human.

Description: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD-1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. PD-1 is thus one of a growing number of immune checkpoint proteins.

Description: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD-1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. PD-1 is thus one of a growing number of immune checkpoint proteins.

Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).

Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).